Bruton’s tyrosine kinase (BTK) is associated with the BCR, and BTK inhibitors have been approved for use in chronic lymphocytic leukemia (CLL) and mantle cell lymphomas but have not been rigorously evaluated in resistant B-ALL (8). Here, BCR is linked to mantle cell lymphoma.